American Society of Hematology

Friday Scientific Workshops

Applications for Friday Scientific Workshops at the 2019 ASH Annual Meeting are now open.

The Friday Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. The 2018 workshops will take place Friday, November 30, 2018, from 1:00 p.m. to 6:00 p.m. in San Diego, California.

All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

For questions about any of the Friday Scientific Workshops, please contact ASH Scientific Programs Specialist Nneka Iwuchukwu at niwuchukwu@hematology.org.

Friday Scientific Workshop on Hematology and Aging: Scientific Advances From Sickle Cell Disease to Malignant Hematology

Friday, November 30, 2018,  1:00 p.m. - 5:45 p.m.
San Diego Convention Center, Room 33B

As the number of older patients with hematologic disorders dramatically increases, large evidence gaps have become apparent. It is crucial to understand the implications of aging on the development, progression, and treatment of hematologic disorders.

The target audience for this workshop includes laboratory-based investigators and clinician researchers with an interest in aging and hematology. However, the wide-ranging content, thematic focus, and interactive format may appeal to a broader audience, including students and trainees.

Workshop Objectives

  • Provide a forum for presentation of novel research related to the biology of aging and hematologic disorders
  • Promote discussion around key items of a newly defined research agenda and call to action, which are based on the past four years of this workshop and were recently published in the Journal of Geriatric Oncology (Rosko et al, 2018)
  • Highlight the areas of overlap and alignment between the hematology and aging research agenda and the ASH Agenda for Hematology Research, including stem cell biology, immunotherapy, and precision medicine
  • Consider opportunities to refine and strengthen ASH's research agenda by incorporating aging-related knowledge gaps
  • Foster collaboration and networking, emphasizing bidirectional translation between pre-clinical and clinical models of aging

This interactive workshop will feature brief didactic presentations from speakers on key topics followed by a few minutes for questions and answers.

Wokshop Schedule


Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Tanya Wildes, MD
Washington University
Saint Louis, MO

As care for sickle cell patients continue to improve, we expect the lifespan of the patients to be extended. This will mean caring for sickle cell patients during their geriatric years. This topic on how to properly care for sickle cell patients as they age has been an area on discussion for many years. We will present expert opinions on this matter in an effort to improve the understanding of this unique population. Dr. Brandon Blue, will be the moderator for the Sickle Cell Disease in the Aging Individual session. Dr. Swee Lay Thien,Dr. John Strouse, and Dr. Payal Desai will discuss various components of caring for aging sickle cell patients. We will conclude the session with discussion from the audience.

Moderator:

Brandon Blue, MD
Moffitt Cancer Center
Tampa, FL

Speakers:

Swee Lay Thein, DSc,FRCP,FRCPath,MBBS,MRCPath,MRCP
National Heart, Lung & Blood Institute
Bethesda, MD
Sickle Cell Disease in the Aging Patient – Where Do We Go from Here?

John J. Strouse, MD, PhD
Duke University School of Medicine
Durham, NC
Geriatric Assessment in Sickle Cell Disease

Andrew I. Schamess, MD
The Ohio State University
Columbus, OH
The Older Sickle Cell Patient: It Takes a Village

Dr. Strouse will describe their on-going study of brief geriatric assessment and resilience in older adults with sickle cell disease. Dr. Schamess will describe a new home-based primary care initiative for adults with sickle cell disease at The James Cancer Hospital and Solove Research Institute at the Ohio State University.

Panelists:

John J. Strouse, MD, PhD
Duke University School of Medicine
Durham, NC

Mikaela D. Moore, BS
The Ohio State University
Columbus, OH

Andrew I. Schamess, MD
The Ohio State University
Columbus, OH

Swee Lay Thein, DSc,FRCP,FRCPath,MBBS,MRCPath,MRCP
National Heart, Lung & Blood Institute
Bethesda, MD

Moderator:

Heidi D. Klepin, MD
Wake Forest University School of Medicine
Winston Salem, NC

Speakers:

Karin L. Gaensler, MD
University of California San Francisco
San Francisco, CA
TriLeukeVax: A Next Generation Autologous Acute Myeloid Leukemia Vaccine for Transplant Ineligible Older Patients

Timothy S. Pardee, MD, PhD
Wake Forest Baptist Health
Winston Salem, NC
Leveraging the Biological Hallmarks of Aging to Improve Outcomes in Elderly Patients with Acute Myeloid Leukemia

Guido Marcucci, MD
City of Hope
Duarte, CA
Aging, Clonal Hematopoiesis and Therapy-related Myeloid Neoplasms: Personalizing the Risk of Chemotherapy Treatments

Martine Extermann, MD
Moffitt Cancer Center
Tampa, FL
Acute Myeloid Leukemia in Older Adults – Surveillance, Epidemiology and End Results-Medicare Modelling of Prognosis

Panelists:

Timothy S. Pardee, MD, PhD
Wake Forest Baptist Health
Winston Salem, NC

Martine Extermann, MD
Moffitt Cancer Center
Tampa, FL

Moderator:

Andrew S. Artz, MD
University of Chicago Hospital
Chicago, IL

Speakers:

Wendy Pang, MD, PhD
Stanford University
Stanford, CA
Strategy for Improving Hematopoietic Stem Cell (HSC) Transplantation in Elderly Myelodysplastic Syndrome (MDS) Patients: Anti-CD117 Antibody to Deplete normal and MDS HSCs

Siddhartha Jaiswal, MD, PhD
Stanford University
Los Altos, CA
Clonal Hematopoiesis in Human Aging and Disease

Thuy T. Koll, MD
University of Nebraska Medical Center
Omaha, NE
An Expanded Framework to Measure Cognitive Function in Older Adults Undergoing Hematopoietic Cell Transplantation

Panelists:

Luigi Racioppi, MD, PhD
University of Naples Federico II
Naples, Italy

Siddhartha Jaiswal, MD, PhD
Stanford University
Los Altos, CA

Thuy T. Koll, MD
University of Nebraska Medical Center
Omaha, NE

Moderator:

Tanya Wildes, MD
Washington University
Saint Louis, MO

Speakers:

Arun P. Wiita, MD, PhD
University of California San Francisco
San Francisco, CA
Enhancing Immunotherapy Efficacy for Aging Myeloma Patients Ineligible for Transplant

Sonja Zweegman, MD, PhD
Vrije Universiteit Amsterdam
Amsterdam, Netherlands
Multiple Myeloma in the Elderly; Beyond Myeloma Biology - Has the Time Come to Implement Biological Markers of Aging?

Ashley E. Rosko, MD
The Ohio State University
Columbus, OH
Gauging Fitness with Biologic Correlates in Multiple Myeloma

Matthew T. Drake, MD, PhD
Mayo Clinic
Rochester, MN
Osteoporosis in Older Adults with Monoclonal Gammopathies

Dr. Rosko will describe the clinical and biologic approach to aging in older adults with multiple myeloma. She will outline a clinical phenotype describing established metrics in the field of geriatric oncology and explore biologic correlates of aging to aid in treatment stratification for older adults with cancer.

Panelists:

Arun P. Wiita, MD, PhD
University of California San Francisco
San Francisco, CA

Sonja Zweegman, MD, PhD
Vrije Universiteit Amsterdam
Amsterdam, Netherlands

Ashley E. Rosko, MD
The Ohio State University
Columbus, OH

Matthew T. Drake, MD, PhD
Mayo Clinic
Rochester, MN

Co-Chairs:

Rebecca L. Olin, MD
University of California, San Francisco
San Francisco, CA

Tanya Wildes, MD
Washington University
Saint Louis, MO

back to top

Friday Scientific Workshop on Inherited Hematopoietic Malignancies

Friday, November 30, 2018,  1:00 p.m. - 6:00 p.m.
San Diego Convention Center, Room 28D

The importance of identifying individuals with germline mutations in genes predisposing to the development of hematopoietic malignancies is increasingly recognized across all age groups. The World Health Organization's revised leukemia classification scheme now includes a provisional category for genetic disorders with risk for myeloid malignancies. In addition to discussing ongoing research efforts in predisposition syndromes, this workshop will address topics on interdisciplinary approaches in establishing a predisposition clinic. The workshop will also feature discussions about ASH's partnership with the Clinical Genome Resource, which will result in consensus-driven collation of variants in genes associated with inherited risk for myeloid malignancies.

Given the expanding role of this topic for clinicians, geneticists, and scientists, the increasing number of recognized syndromes, and the existence of new initiatives, this workshop will appeal to a multidisciplinary audience from many countries.

Workshop Objectives

  • To discuss on-going research efforts in specific predisposition syndromes
  • To strengthen existing and to develop new collaborations in these diseases
  • To discuss interesting pedigrees that have tested negative for all known predisposition alleles to date and to combine pedigrees with similar phenotypes
  • To inform ASH members who are clinicians about these predisposition syndromes and provide contacts to facilitate testing and expand research
  • To discuss sequencing approaches, limitations, timing, and circumstances for variant evaluation

The workshop will be conducted with an interactive format, encouraging input from the participants.

Wokshop Schedule


Co-Chairs:

Lucy A. Godley, MD,PhD
University of Chicago Medical Center
Chicago, IL

Marcin W. Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

This session is meant as a practical guide for attendants as they prepare to implement genetic counseling and testing locally. It will involve specialists from several centers so that the audience can compare and learn about required infrastructure and anticipated problems while establishing a predisposition clinic. The session will include various types of practitioners, e.g., genetic counselor, nurse practitioner, pediatric hematologist/oncologist, adult hematologist/oncologist.

Moderators:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

Kim E. Nichols, MD
St Jude Children's Research Hospital
Memphis, TN

Speakers:

Marshall S. Horwitz, MD, PhD
University of Washington
Seattle, WA
Establishing a Hematological Malignancy Clinic at the Seattle Cancer Care Alliance

Panagiotis Baliakas, MD, PhD
Uppsala University
Uppsala, Sweden
Dealing with Hematological Malignancies with Germline Predisposition in Routine Clinical Practice

Emily Quinn, MS
Keck Graduate Institute
Claremont, CA
Incorporating Genetic Counselors into the Hematopoietic Predisposition Malignancies Clinic

Michelle Boals, MSN
St. Jude Children's Research Hospital
Memphis, TN
Incorporating Nurse Practitioners into the Hematopoietic Malignancies Predisposition Clinic

Moderators:

Marcin W. Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

Kaan Boztug, MD
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases
Vienna, Austria

Speakers:

Michelle L. Churchman, PhD
St. Jude Children's Research Hospital
Memphis, TN
Acute Lymphoblastic Leukemia (ALL) Predisposition: Germline Genetic IKZF1 Variation and Predisposition to Childhood ALL

Paul P. Liu, MD
National Institutes of Health
Bethesda, MD
Establishing an FPDMM Program in the NIH Clinical Center

Abhishek A. Mangaonkar, MD
Mayo Clinic
Rochester, MN
Recognition of Inherited Bone Marrow Failure Syndromes through a Genomics Approach for Patients with Unexplained Cytopenias: Experience and Clinical Utility of a Precision Genomics Clinic

Rakesh K. Goyal, MBBS,MD,MRCP
Children's Mercy Hospital
Kansas City, MO
Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations

Moderators:

Sharon A. Savage, MD
National Cancer Institute
Bethesda, MD

Ian Majewski, PhD
The Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia

Speakers:

Anna Byrjalsen, MD
Rigshospitalet
Copenhagen East, DNK
Update from the Staging Study: A Case of Germline Bi-Allelic Mutations in DDX41- a Putative Novel Childhood Leukemia Predisposition Gene

Mathijs A. Sanders, PhD, MSc
Erasmus University Medical Center
Rotterdam, Netherlands
MBD4 in Inherited Myeloid Malignancy

Fernanda Martins Rodrigues, MSc
Washington University in St. Louis
Saint Louis, MO
Germline Variants in Multiple Myeloma

Ensi Voshtina, DO
Medical College of Wisconsin
Milwaukee, WI
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results

Dan Liu
Chinese Academy of Sciences
Beijing, China
APP As a Candidate Familial Eosinophilia Predisposition Gene

Moderators:

Hideki Muramatsu, MD, PhD
Nagoya University Graduate School of Medicine
Nagoya, Japan

Shannon K. McWeeney, PhD
Oregon Health & Science University
Portland, OR

Speakers:

Michael C. Chicka, PhD
Prevention Genetics
Marshfield, WI
ClinGen Update

Chimene Kesserwan, MD
St. Jude Children's Hospital
Memphis, TN
ClinGen Update

Anna L. Brown, PhD,BSc
Centre For Cancer Biology, SA Pathology/IMVS
Adelaide, SA, Australia
Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy- the RUNX1.db

This session will cover ethical considerations regarding the benefits and challenges surrounding genetic testing of patients, stem cell transplant donors and carriers. It will also address different genetic testing practices and possible solutions to support the best interest of patients and family members with inherited predisposition to hematologic malignancies.

Moderators:

Inga Hofmann, MD
University of Wisconsin
Madison, WI

Sarah Bannon, MS
The University of Texas MD Anderson Cancer Center
Houston, TX

Moderators:

Timothy S. Olson, MD, PhD
The Children's Hospital of Philadelphia
Philadelphia, PA

Mary Y. Armanios, MD
Johns Hopkins University
Baltimore, MD

Speakers:

Elissa M. Furutani, MD
Boston Children's Hospital
Boston, MA
Pilot Study of Metformin in Fanconi Anemia

Raffaele Renella, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland
Seizing Opportunities in the Molecular and Cellular Dissection of Unique Phenotypes in Pediatric Myelodysplastic Syndromes

Adam J. de Smith, PhD
University of Southern California
Los Angeles, CA
Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia

Ulla Wartiovaara-Kautto, MD, PhD
University of Helsinki
Helsinki, Finland
Joint Pediatric and Adult Rare Hematological Disorders Outpatient Clinic in Helsinki University Hospital: Experiences and Scientific Discoveries

Co-Chairs:

Lucy A. Godley, MD,PhD
The University of Chicago
Chicago, IL

Marcin W. Wlodarski, MD, PhD
St. Jude Children's Research Hospital
Memphis, TN

back to top

Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact

Friday, November 30, 2018,  1:00 p.m. - 6:00 p.m.
San Diego Convention Center, Room 24B

Epidemiologic research is of increasing importance in the era of large-scale genomics and databases, where large numbers of patients must be accumulated to study subtle individual effects that translate into large population effects. Population studies can identify risk predictors for disease, progression, and outcome, which may have a substantial impact on treatment decisions (risk stratification) and prevention. This workshop will provide a forum for epidemiologists working on hematologic neoplasms to present timely research topics from big data to molecular studies (DNA methylation, biomarkers, germline/tumor genetics, microbiome, etc.) applied to large populations. The workshop will address fundamental questions regarding the development and prevention of hematologic malignancies in populations with an emphasis on translational potential. In addition, this workshop will provide an opportunity for basic scientists to present work that could be applied to large-scale population studies, translating from the bench to the real-world population.

This workshop is directed at epidemiologists focused on hematologic neoplasms as well as basic and clinical scientists interested in real-world population applications of their findings. The workshop will also appeal strongly to trainees in clinical hematology-oncology who are interested in expanding their careers to include an epidemiologic focus.

Workshop Objectives

  • To provide a unique forum at the ASH annual meeting to discuss and present advances in the field of epidemiology of hematologic malignancies
  • To extend novel observations generated from epidemiology studies to translational studies with direct clinical relevance and to provide an opportunity to integrate new molecular or bench findings into population studies
  • To develop a roadmap and future directions that advance the study of epidemiology, particularly including prevention strategies for lymphoid and myeloid malignancy and associated diseases
  • To establish a forum that enhances current collaborations, develops new collaborations, and provides opportunities for career development and research for trainees and junior investigators in the field of epidemiology of hematologic malignancy

The workshop will be comprised of two consecutive sessions, each with eight speakers giving focused, 10- to 15-minute, cutting-edge presentations on the clinical and molecular epidemiology of hematologic malignancy. The presentations will include audience/attendee interaction and discussion, followed by a panel discussion at the end of each session to generate collaboration and translation.

Wokshop Schedule


Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA

Moderators:

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA

Speakers:

Sophia S. Wang, PhD
City of Hope
Duarte, CA
Human Leukocyte Antigen Diversity As a Risk Factor for Lymphoma

Maher K. Gandhi, PhD
University of Queensland Diamantina Institute
Brisbane, QLD, Australia
Immunologic Predictors of Outcome in Non-Hodgkin and Hodgkin Lymphoma: Are Population-Based Studies Possible?

Juan Manuel Mejia-Arangure, PhD
Instituto Mexicano del Seguro Social
Mexico, DF, MEX
Molecular Epidemiology of Pediatric Leukemias in Mexico

Karin E. Smedby
Karolinska University Hospital
Stockholm, Sweden
Population-Based Studies of Diffuse Large B-Cell Lymphoma Outcomes in Sweden with a Focus on the Elderly Patients

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA
Stand up to Cancer: Citizen Science to Discover Predictors of Monoclonal Gammopathy of Undetermined Significance (MGUS) and MGUS Progression

Alyssa I. Clay-Gilmour, Ph.D
Mayo Clinic
Rochester, MN
Extending Genome Wide Association Studies of Multiple Myeloma to Elicit Clues to Etiology

Elizabeth E. Brown, PhD, MPH
University of Alabama at Birmingham
Birmingham, AL
DNA Methylation Patterns in Monoclonal Gammopathy of Undetermined Significance and Myeloma Predicts Progression

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA
EBV Viral Load, EBV Tumor Status and Germline Genotype in U.S. and French Adolescent/ Young Adult Hodgkin Lymphoma Patients

Panelists:

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA

James R. Cerhan, MD, PhD
Mayo Clinic
Rochester, MN

Moderators:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Lindsay M. Morton, PhD
National Cancer Institute, NIH, DHHS
Bethesda, MD

Speakers:

Catherine Metayer, MD, PhD
University of California Berkeley
Berkeley, CA
Update on Epidemiology of Pediatric Acute Myeloid Leukemia

Kelly Bolton, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Clonal Hematopoiesis As a Disease Risk Factor Following Chemotherapy and Radiotherapy

Koichi Takahashi, MD
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Clonal Hematopoiesis As an Acute Myeloid Leukemia Risk Factor and Extending to Its Impact on Minimal Residual Disease and Outcome after Therapy

Lindsay M. Morton, PhD
National Cancer Institute, NIH, DHHS
Bethesda, MD
The Epidemiology of Therapy-Related Myeloid Malignancy in the Modern Treatment Era

Nandita Khera, MD
Mayo Clinic
Phoenix, AZ
Impact of Disparities and Access to Allogeneic Transplantation for Acute Myeloid Leukemia

Lara E. Sucheston-Campbell, PhD,MS
Cancer Prevention & Control
Columbus, OH
Molecular Epidemiology of Acute Myeloid Leukemia - GEMM Consortium

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL
Clinical Risk Factors and Association with Cytogenetic & Molecular Phenotype and Outcome in Acute Myeloid Leukemia

Alexandra Smith, PhD
University of York
York, United Kingdom
Real World Epidemiology of Myeloid Malignancy – Incidence and Outcomes

Co-Chairs:

James M. Foran, MD
Mayo Clinic Florida
Jacksonville, FL

Wendy Cozen, DO,MPH
University of Southern California
Los Angeles, CA

back to top

Friday Scientific Workshop on Myeloid Development

Friday, November 30, 2018,  1:00 p.m. - 5:50 p.m.
San Diego Convention Center, Ballroom 20A

This workshop will examine the latest scientific findings in myeloid biology in a highly interactive environment that permits exchange of ideas among investigators. The workshop will focus on topics such as hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology. Each session leader will briefly summarize the current questions facing the field and then lead discussions on how best to answer those questions. New findings or novel techniques that provide insight into these questions will be an essential part of all discussions. The research presented at this workshop will also focus on the use of molecular biology and biochemistry tools, as well as animal models, to address the core topics; it will not include any purely clinical, epidemiologic, or population-based approaches.

This workshop is directed at laboratory-based investigators, but the broad-ranging content and highly interactive format is suitable for clinically oriented investigators and is particularly appealing to young investigators, as it provides the opportunity to interact directly with experts in the field.

Workshop Objectives:

  • Discuss the latest scientific developments in hematopoietic stem cell biology, leukemogenesis, cell signaling, transcription factors, epigenetic effects, and other topics related to myeloid biology
  • Have interactive presentations by world-class scientists
  • Provide young investigators opportunities to interact with world-renowned experts in the field

The format of this workshop will include brief didactic sessions followed by a couple of minutes for questions and answers.

Wokshop Schedule


Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Leonard Zon, MD
Harvard University
Boston, MA

Moderator:

Patricia Ernst, PhD
University of Colorado Denver
Aurora, CO

Speakers:

Linda Resar, MD
Johns Hopkins University SOM
Baltimore, MD
High Mobility Group A1 Chromatin Remodeling Protein Deficiency Results in Global Defects in Stem Cell Function and Premature Aging Phenotypes

Guy Sauvageau, MD
The Leucegene Project at the Institute for Research in Immunology and Cancer (IRIC)
Montréal, QC, Canada
UM171 in 420 Seconds

Hanna Mikkola, MD, PhD
University of California, Los Angeles
Los Angeles, CA
Human Hematopoietic Stem Cell Self-Renewal and Engraftment Are Enhanced By the Transcriptional Regulator MLLT3

Yan Liu, PhD
ndiana University School of Medicine
Indianapolis, IN
Mutant p53 Promotes Hematopoietic Stem and Progenitor Cell Expansion through Interacting with Epigenetic Modulator EZH2

Moderator:

Claudia Lengerke, MD
University Hospital Basel
Basel, Switzerland

Speakers:

Eirini Trompouki, PhD
Max Planck Institute of Immunobiology and Epigenetics
Freiburg, Germany
Role of RIG-I-like Receptors in Developmental Hematopoiesis

Trista E North, PhD
Boston Children's Hospital
Boston, MA
YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biophysical Forces of Blood Flow

Shannon McKinney-Freeman, PhD
St. Jude Children's Research Hospital
Memphis, TN
The Global Clonal Complexity of the Murine Blood System Declines throughout Life and after Serial Transplantation

Simon Mendez-Ferrer, PhD
Centro Nacional De Investigaciones Cardiovasculares
Cambridge, ENG, Spain
The Bone Marrow Microenvironment Promotes Myeloid Differentiation During Premature or Physiological Aging

Moderator:

Nancy E. Speck, PhD
University of Pennsylvania
Philadelphia, PA

Speakers:

Zuzana Tothova, MD, PhD
Dana-Farber Cancer Institute
Cambridge, MA
STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

Anna E. Beaudin, PhD
University of California Merced
Merced, CA
The Lymphoid Associated IL7R Regulates Tissue Resident Macrophage Development

Christopher M. Sturgeon, PhD
Washington University School of Medicine
St.Louis, MO
Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Chun-Wei Chen, PhD
City of Hope
Duarte, CA
High-Density CRISPR Scan Identifies Functional Regions of DOT1L That Mediate Therapeutic Response in MLL-r Leukemia

Katie Kathrein, PhD
University of South Carolina
Columbia, SC
Ing4 Regulates Hematopoiesis through Suppression of NF-Kb

Speakers:

Cindy N. Roy, PhD
National Institute of Diabetes, Digestive, and Kidney Disease
Bethesda, MD
NIDDK Presentation

Pankaj Qasba, PhD
National Institutes of Health
Bethesda, MD
NHLBI Presentation

Moderator:

Ulrich G. Steidl, MD, PhD
Albert Einstein College of Medicine
Bronx, NY

Speakers:

Mark Dawson, PhD, MBBS
Peter MacCallum Cancer Centre
Melbourne, AUS
Non-Genomic Mechanisms of Therapeutic Resistance

Shannon M. Buckley, PhD
University of Nebraska Medical Center
Omaha, NE
Ing4

Daisuke Nakada, PhD
Baylor College of Medicine
Houston, TX
PRDM16 Changes the Fate of Megakaryocytic Cells to Acute Myeloid Leukemia Initiating Cells

Margaret H. Baron, MD
Mount Sinai School of Medicine
New York, NY
Stimulation of the Proliferation of Mouse and Human Definitive Erythroid Progenitors By Activation of the Vitamin D Receptor Transcription Factor

Moderator:

Benjamin L. Ebert, MD,PhD
Harvard Medical School
Boston, MA

Speakers:

Warren S. Pear, MD,PhD
University of Pennsylvania
Philadelphia, PA
Oncogenic Notch Promotes Long-Range Regulatory Interactions within Hyperconnected 3D Cliques

Maria E. Figueroa, MD
University of Miami
Miami, FL
Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers Linked to Cancer Pathways

Thomas Mercher, PhD
Institut Gustave Roussy
Villejuif, France
Ontogeny-Dependent Susceptibility to Fusion Oncogenes Controls Pediatric Myeloid Leukemia

Jeffrey W. Tyner, PhD
Oregon Health & Science University
Portland, OR
Leveraging of the Beat Acute Myeloid Leukemia 1.0 Dataset to Understand Drug Sensitivity and Resistance

Co-Chairs:

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Leonard Zon, MD
Harvard University
Boston, MA

back to top

Friday Scientific Workshop on Tumor Immune Interactions in Lymphoid Malignancies

Friday, November 30, 2018,  1:00 p.m. - 5:30 p.m.
San Diego Convention Center, Ballroom 20D

The area of immunotherapy in lymphoid malignancies has exploded in recent years. Multiple new immune therapies are in development in lymphoproliferative diseases, and this exciting progress has been due to an increased understanding of the tumor microenvironment and tumor-immune interactions in these diseases. This proliferation of scientific knowledge has led to multiple potential new treatments, including new immune checkpoint blockade therapies, novel T-cell approaches, agents targeting monocytes, and macrophages, as well as new approaches inhibiting immune receptors and cytokine signaling.

The target audience for this workshop is laboratory-based investigators who are interested in myeloid biology. The workshop’s presentations and discussions focus solely on the basic science of myeloid development; there are no presentations on clinical/treatment strategies. Attendees benefit from interactive presentations by world-class scientists. The workshop reinforces the appeal of attending the ASH annual meeting by scientists from around the world, and it can serve as an introduction to the scientific content that will be presented at the ASH annual meeting.

Workshop Objectives:

  • Highlight novel basic science and translational immune research in lymphoid malignancies that are likely to translate in the near future to clinically relevant therapies, biomarkers, or correlative science
  • Feature new methods of immune monitoring, as well as potential future therapies or therapeutic targets that are likely to be important in lymphoid malignancies

The workshop's aim is to have scientists, translational researchers, and clinicians "hear it here first" when it comes to the next big thing in the management of lymphoid diseases. This workshop will be highly interactive and somewhat speculative (though based on science), with a strong focus on future translation immune-related research into the clinic.

Wokshop Schedule


Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Ash A. Alizadeh, MD,PhD
Stanford University
Stanford, CA
Immune Cell Deconvolution By Learning from Single Cells

Kojo S. J. Elenitoba-Johnson, MD
University of Pennsylvania
Philadelphia, PA
Using Functional Proteogenomics to Identify Biomarkers and Therapeutic Targets in Lymphoma

The goal of the workshop is to highlight exciting new areas of translational research as it relates to the tumor microenvironment with a focus on lymphoid malignancies.

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Ahmed Sawas, MD
Columbia University Irving Medical Center
New York, NY
Engaging Natural Killer Cells in T-Cell Lymphoma

Bob Uger, PhD
Trillium Therapeutics Inc.
Mississauga, ON, Canada
CD47 Directed Therapy in B-Cell Malignancies

Moderators:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

Speakers:

Marco Ruella, MD
University of Pennsylvania
Philadelphia, PA
Overcoming the Immunosuppressive Microenvironment in Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Becker Hewes, MD
Torque Therapeutics
WINCHESTER, MA
Cell-Based Delivery Systems in Lymphoid Malignancies

Co-Chairs:

Stephen M. Ansell, MD, PhD
Mayo Clinic
Rochester, MN

Ronald Levy, MD
Stanford University
Stanford, CA

back to top